Tel Aviv, July 22, 2025 - SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company received a notification from The Nasdaq Stock Market LLC on July 18, 2025, confirming that its ordinary shares maintained a closing bid price of at least $1.00 for 10 consecutive business days. This compliance resolves the prior bid price deficiency issue, and Nasdaq now considers the matter closed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9498357-en) on July 22, 2025, and is solely responsible for the information contained therein.